Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Instituto do Cancer do Estado de São Paulo
National Institutes of Health Clinical Center (CC)
Eastern Cooperative Oncology Group
Pfizer
Pfizer
Stanford University
University of Nebraska
Adela, Inc
Degron Therapeutics Co.
The University of Texas Health Science Center at San Antonio
Jonsson Comprehensive Cancer Center
Azienda Ospedaliera di Padova
Apollomics Inc.
Columbia University
Algemeen Ziekenhuis Maria Middelares
Children's Hospitals and Clinics of Minnesota